Status:
COMPLETED
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
Lead Sponsor:
Cassella-med GmbH & Co. KG
Conditions:
Atypical Depression
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.
Detailed Description
The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reve...
Eligibility Criteria
Inclusion
- Main Inclusion Criteria:
- Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months
- Female and male Caucasians aged 18 to 70 years
- At least one of HAMD-28 scale items 22-26 scores \>1
Exclusion
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT00861978
Start Date
December 1 2002
End Date
November 1 2004
Last Update
March 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.